The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants

Shalabh Singhal(Integrated BioTherapeutics (United States)), John Throup(Bristol-Myers Squibb (United States)), Jenny Xie(Bristol-Myers Squibb (United States)), Santanu Dutta(Bristol-Myers Squibb (United States)), Diane E. Shevell(Bristol-Myers Squibb (United States)), Ihab Girgis(Bristol-Myers Squibb (United States))
Expert Opinion on Investigational Drugs
April 2, 2020
10.1080/13543784.2020.1742322
Cited by 4

Related Papers

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
|Annals of the Rheumatic Diseases|2022|19
POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
|Annals of the Rheumatic Diseases|2021|15